Two-pronged Antibody Can Help Efficiently Destroy Ovarian Cancer Cells, Researchers Find

Two-pronged Antibody Can Help Efficiently Destroy Ovarian Cancer Cells, Researchers Find
A newly developed two-pronged antibody is 100 times more effective at destroying ovarian cancer cells than other antibodies in clinical trials, according to researchers at the University of Virginia School of Medicine. Their study, “A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer,” was published in the journal Cancer Cell. Antibodies that selectively target and eliminate cancer cells have been gaining traction in the research world in recent decades. These antibodies are targeted toward specific receptors (proteins) that are displayed on the surface of tumor cells. However, antibodies designed to target receptors on ovarian cancer cells such as the folate receptor alpha-1 (FOLR1) and cancer antigen 125 (Ca125) have largely been disappointing in clinical trials. One of the reason why the clinical response has not been beneficial is because the immune cells have a hard time infiltrating into the tumor environment. “I found that one of the problems is with the solid tumor microenvironment,” Jogender Tushir-Singh, corresponding author of the study, said in a UVA news story by Josh Barney. “The microenvironment is highly hypoxic, anergic and, particularly in the case of ovarian cancer, some unusually large receptors form a protective fence around tumor cells, so even if the immune cells reach there, there are many obstacles,” he added. Interestingly
Subscribe or to access all post and page content.

Tagged , , .

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

Leave a Comment

Your email address will not be published. Required fields are marked *